onc brain

The longer read

The question PACE-B's PROM report actually answers is narrower than its cross-modality framing suggests, and it is the more useful of the two. Ultrahypofractionation to 36.25 Gy in five fractions has been adopted on efficacy non-inferiority, but the earlier physician-reported signal of higher cumulative GU adverse events left an open worry that the convenience was being paid for in late urinary function. At 5 yr the patient-reported data do not support that worry. Leak-free rates were 64% versus 69%, pad-free 91% versus 90%, and the combined leak- and pad-free endpoint identical at 88%; the difference in proportions for that combined endpoint was +0.08% with a confidence interval spanning roughly six points either way. The transient 2-yr excess in moderate or big leakage problems after SBRT, which mirrored the clinician-reported GU events, had converged by 5 yr. That trajectory matters more than any single timepoint: it recasts the known GU signal as an early and intermediate phenomenon rather than a durable deficit, which is precisely the distinction a patient weighing five visits against twenty or thirty-nine needs.

How much should the nonsignificance move confidence? Less than the headline implies, and in a specific direction. EPIC-26 completion fell to 62% and 58% by 5 yr, so each proportion rests on roughly 250 respondents out of 433 and 441 allocated. Responder attrition in functional outcome studies is not plausibly random, and the leak-free comparison carries a five-point nominal gap favouring CRT with an interval reaching +13.72%. This analysis is powered to exclude a large difference, not a clinically meaningful modest one, and "no significant difference" here should be read as compatible with a small disadvantage in either direction. The open-label allocation compounds this for subjective self-report, though the direction of any expectation bias in a trial where the shorter schedule is the novel arm is not obvious.

A second gap constrains the read more sharply than the statistics do. The EPIC-26 irritative and obstructive domain was not collected. Urgency, frequency and flow are the symptoms that dominate the post-SBRT complaint profile, and their omission means the domain where the physician-reported excess most plausibly lived is the one domain unmeasured in this report. The authors note that no difference was seen at 5 yr in the prior PACE-B analysis, which is reassuring but is not the same as having those data alongside the continence and bowel results presented here. Nor is image-guidance method analysed, so the result should be read as belonging to the standard of delivery achieved across the trial's centres rather than to any particular platform or margin.

The cross-modality alignment with TrueNTH is the paper's stated novelty and the part that should be held loosest. The instrument and the visual presentation match, but a 1-yr surgical cohort compared with a 5-yr radiotherapy cohort from a different study is a benchmark, not a comparison; the gap it displays in continence and potency runs in the direction that PACE-A's randomised pad-use figures already showed, which is why the framing is credible even where the design is not. Nothing here speaks to high-risk disease, nodal coverage, or the patients for whom the surgery-versus-radiotherapy decision is genuinely contested. For the low- and intermediate-risk man choosing a fractionation schedule, though, the late functional argument for the longer course has now largely gone.